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ChondrosarcomaPurpose: The development of novel and efficient biomarkers for primary bone cancers is of grave impor-
tance.
Methods: The expression pattern of osteopontin (OPN) was investigated in the 153 patients with benign
(n = 72) and malignant (n = 81) primary bone cancers. Both local and circulating OPN mRNA expression
levels and their protein concentration in serum and tumor site were assessed using real-time qRT-PCR,
ELISA, and immunohistochemistry techniques, respectively. As a control, 29 healthy individuals were
considered. The number of 153 tumor tissue specimens and the 153 paired margins were taken on sur-
gical resection from the patients. 153 blood samples were also drained from all participants, then periph-
eral blood mononuclear cells (PBMC) and sera were separated.
Results: The mean mRNA expression was significantly higher in all of the cancerous tissues than the
paired margins and the PBMC of the patients than the controls. Consistently, the protein concentrations
of OPN in serum and tumor tissues were significantly higher in the patients. Furthermore, the malignant
cases had significantly elevated the mRNA levels and the protein compared to the benign cases. OPN
could potentially differentiate the patients from the controls with 100% sensitivity and specificity in
serum. Moreover, OPN could predict some of the malignant cases’ clinicopathological features, including
metastasis, recurrence, grade, and response to chemotherapy.
Conclusions: In conclusion, OPN might be involved in the pathogenesis of primary bone tumors and can
be considered as a potential biomarker to bone cancer diagnosis.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction were responsible for 3,500 new cancer cases and 1,660 deaths inPrimary bone and joint malignancies are the third leading cause
of death in cancer patients under 20 years of age [1]. These tumorsthe United States in 2019 [2]. Primary skeletal tumors are mainly
diagnosed through imaging and biopsy; therefore, less invasive
diagnostic techniques are urgently demanded. Moreover, the han-
dling of bone tumors is considered a big challenge for oncologists
and surgeons due to their diverse histological natures and different
clinical manifestations. Additionally, because of the limited ability
to remove or manage the tumors, the mortality rate is relatively
high in these patients. Although tremendous progress has been
made within the past decade, there are currently no specific mark-
ers that can reliably be employed to diagnose bone tumors. Such
biomarkers would significantly decrease mortality and increase
limb salvage strategies. Furthermore, early detection of either
recurrent or metastatic disease can contribute to timely decisions
and action to treat the tumor, improving patient prognosis [3,4].
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rich, chemokine-like, matricellular phosphoglycoprotein that facil-
itates cell-matrix interactions and promotes tumor progression [5].
It is expressed by many normal cells, particularly those originating
from bone and immune systems, including fibroblasts, osteoblasts,
osteocytes, hypertrophic chondrocytes, dendritic cells, macro-
phages, smooth muscle cells, and activated T cells [6]. OPN is a
multifunctional cytokine that plays a significant role in cell prolif-
eration, survival, drug resistance, invasion, and stem-like behavior
[7]. Considering its vital role in regulating cell fate, its abnormal
expression and/or splicing is involved in undesirable alterations
in disease pathologies, specifically cancer[8]. In this regard, OPN
has been identified in various types of human carcinomas, where
its overexpression was associated with a colon[9], bladder [10],
breast[11], gastric , and liver[12] cancer progression. . Further-
more, using the MICROMAX complementary DNA (cDNA) microar-
ray system, Wong et al. (2001) identified 30 putative genes,
including OPN, that are differentially overexpressed in ovarian can-
cer cell lines[13]. It has also been demonstrated that OPN increased
expression induced tumor cell invasion and migration through
induction of PI3K signaling and Matrix metallopeptidase 9
(MMP9) activity in colon cancer[9]. Moreover, the simultaneous
over-expression of OPN and up-regulation of MMP9 and S100
calcium-binding protein A8 (S100A8) was associated with tumor
grade and shorter survival time of patients with bladder cancer
[10].
Despite its crucial role in the pathophysiology of primary bone
tumors, the diagnostic and prognostic values of OPN have not yet
been adequately addressed in the patients with various primary
skeletal cancers, and the available studies are mainly limited to a
single type of tumor, with osteosarcoma dominating the literature
landscape [14]. More importantly, the efficacy of OPN in predicting
outcomes of the disease remains unclear. Therefore, we aimed at
these shortcomings and designed this comparative study to 1)
determine the gene and protein expression pattern of OPN in dif-
ferent malignant and benign primary bone cancers 2) determine
the the relevance ofOPN expression to the clinicopathological fea-
tures of the malignant cases, including metastasis, recurrence,
grade, and response to chemotherapy. To get valuable insight into
the efficacy of OPN as a biomarker in primary bone cancer , its level
was measured in three different sites, including the tissue speci-
mens (tumor and paired margin), peripheral blood mononuclear
cells (PBMC), and serum.2. Materials & Methods
2.1. Patients and sample collection
A total of 153 patients suffering from malignant (n = 81) and
benign (n = 72) primary bone cancers were enrolled in the study.
The demographic data and history of the participants can be found
in table 1. Moreover, 29 healthy age and sex-matched individuals
were considered as the control group. . Following surgical resec-
tion, fresh pair of the tumor and marginal tissue were taken from
all the 153 patients who were subjected to surgery at Shafa Ortho-
pedic Hospital. A part of the tumor and margin tissue of each
patient was transferred to the pathology department for further
histological evaluations and immunohistochemistry evaluations
and the rest were immediately transferred to the lab in a cool sit-
uation and kept at 80 for gene expression evaluation. Further-
more, to evaluate the serum level of OPN, the 6 ml of peripheral
blood were drained from all the patients and controls and trans-
ferred to the laboratory immediately , and subjected to serum sep-
aration by centrifuge for 10 min at approximately 1000g [15]. The
serum samples were stored at 80 C until evaluation with appro-2
priate indications and labeling. Moreover, the total amount of 6 ml
peripheral blood was taken from the patients and healthy controls
and applied for the peripheral blood mononuclear cell (PBMC) sep-
aration. The clinic- pathological features of the patients with
malignant/benign bone tumors are summarized in table 1 and
the biochemical profile of the patients is presented in table 2.
2.2. Separation of PBMC
Ficoll-Hypaque density gradient centrifugation method (Sigma
Chemical Co, St Louis, MO, USA, Cat No. # 10771) was used for
PBMC separation from the blood samples[16]. Based on this
method, freshly drawn 6 ml of peripheral blood samples of each
patient and control were collected and diluted 1:1 in phosphate-
buffered saline (PBS). Then the diluted blood was gently added to
the tube containing Ficoll (3 ml) and centrifuged at 2700 g for
40 min in a refrigerated centrifuge. After centrifugation, the layer
containing peripheral blood mononuclear cells were removed
and poured into a separate tube. The cells were washed with
(PBS) and finally centrifuged at 3200 g for 5 min and counted by
hemocytometer. The same number of cells were used for RNA
extraction.
2.3. Assessment of biochemical profile and serum OPN level
Creatine phosphokinase (Cat No. # 1050016), alkaline phos-
phatase (Cat No. # 5018) , lactate dehydrogenase (Cat No. #
1400022), calcium (Cat No. # 1100008), inorganic phosphorus
(Cat No. # 140020) were measured using the available standard
assay kits (PARS AZMUN, Tehran, Iran) according to the manufac-
turer’s recommendations. sodium and potassium. . Blood elec-
trolytes including sodium and potassium were measured
photometrically. Briefly, an ion Selective Electrode is placed in
the sample and due to the passage of the desired ions through a
membrane (due to the concentration gradient), a potential differ-
ence occurs on both sides of the membrane. The voltage of this cur-
rent is proportional to the logarithm of the desired electrolyte
concentration. Additionally, serum OPN level was measured using
a Human Osteopontin Assay Kit (IBL, Japan) (Cat No. # 27158) with
an analytical sensitivity of 5 ng/mL (Interassay CV: 7.8% & Intraas-
say CV: 4.7%). The basis of this kit is a sandwich method using a
monoclonal antibody. Anti-OPN antibodies were coated directly
on the solid surface of the plates and following adding a serum
and the provided standards to the plate, the secondary antibodies
conjugated to HRP (horseradish peroxidase) were applied. The HRP
antigen–antibody complex produces color by acting on the sub-
strate. Tetramethyl benzidine was used as a staining agent (chro-
mogen). The color intensity was proportional to the amount of
OPN in the serum. The optical absorption of standards and samples
was read at a wavelength of 450 nm via a microplate reader.
2.4. RNA extraction, cDNA synthesis, and Real-Time PCR
Total RNA was extracted from the tissue samples (tumors and
margins) and PBMC via Trizol (Invitrogen, Grand Island, USA Cat
No. # 15596026) according to our previously described procedure
for measuring the SOX9 gene expression [17]. Total RNA (1 mg of
each sample) was used to synthesize cDNA with PrimeScript First
Strand cDNA Synthesis Kit (Takara, Japan, Cat No. # 6110A) accord-
ing to the manufacturer’s instructions. OPN expression levels were
quantitated with SYBR Premix Ex Taq II (Takara, Japan, Cat No. #
RR820A), which was performed in Applied Biosystems Step One
Plus, Real-time system (Applied Biosystems, USA). The sequences
of the designed primers are shown in table 3. The reactions were
set up as follows: 95 C for 5 min following 40 cycles at 95 C for
5 s, 55 C for 20 s, and 60 C for 35 s. Beta-Actin was used as a
Table 1
The demographic data of the patients with different bone cancers.
Variable Age Gender Tumor grade Metastasis Chemotherapy Recurrence
Patient Group 40 40 Male Female Low High Positive Negative Positive Negative Positive Negative
Osteosarcoma
(n = 27)
12 15 13 14 9 18 10 17 18 9 7 20
Chondrosarcoma
(n = 27)
0 27 16 11 15 12 8 19 0 27 0 0
Ewing sarcoma
(n = 27)
15 12 17 10 8 19 10 17 15 12 7 20
Exostosis (n = 24) 13 11 15 9 0 0 0 0 0 0 0 0
Giant Cell Tumor
(n = 24)
8 16 16 8 0 0 0 0 0 0 0 0
Osteochondroma
(n = 24)
6 18 15 9 0 0 0 0 0 0 0 0
Table 2
The biochemical profile of the enrolled patients (n = 153).











































































The primer sets used in this study for qRT-PCR assay.
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gene. The formula RQ = 2-DCT was used to analyze the relative gene
expression levels after normalization with the endogenous con-
trols and the OPN and beta-actin melt curves were considered as
primer specificity.Beta-Actin Forward
Reverse
5-GAT CTC CTT CTG CAT CCT GT-30
50-TGG GCA TCC ACG AAA CTA C- 30
572.5. Immunohistochemistry
The local protein expression level of OPN in tumor and marginal
tissues were assessed using immunohistochemistry. Briefly, the
frozen tissue blocks were prepared using Optimal Cutting Temper-
ature (OCT) embedding medium and fixed in 4% paraformalde-
hyde, and incubated in 20% sucrose. The cryotome was used to
prepare 10 nm tissue sections and the slides were washed with
PBS and exposed to Triton 3% for 30 min. Triton is used to induce
cell membrane permeable to antibodies. In the next step, 10% goat
serum was added to the cells for half an hour to block the non-
specific antigenic sites. The dilution of 1:100 of a monoclonal anti-
body of OPN (Santa Cruz Biotechnology, USA, Cat No. # SC-21742)
was used for staining in a proper incubation time and the goat anti-
mouse IgG-FITC secondary antibody (Santa Cruz Biotechnology,
USA, Cat No. # SC-2010) was applied with a delusion of 1:200 in
dark at 37 C. Following adequate washing with PBS (3 times),
the 40,6-Diamidine-20-phenylindole dihydrochloride (DAPI) (Sigma,
Germany,
Cat No. # 28718–90-3) was used to stain the nuclei and then
evaluated with a fluorescent microscope. The staining intensity3
of OPN was quantified using ImageJ and reported as the percentage
of positive reactivity[18].2.6. Statistical analysis
Statistical analysis was performed using commercially available
software (GraphPad Prism version 8.0.2, GraphPad Software, San
Diego, California). All data were examined for normal distribution
using an examination of the residuals and a D’agostino-Pearson
omnibus test. Considering the non-Gaussian distribution of the
data, multiple comparisons were carried out using the nonpara-
metric Kruskal-Wallis test by controlling the false discovery rate
and calculating exact P-values (q-values). Side-to-side compar-
isons were conducted using the parametric unpaired t-test and
nonparametric Mann–Whitney U test. The receiver operating char-
acteristic (ROC) curves and calculation of area under the curve
(AUC) were applied to calculate the diagnostic value of OPN gene
expression in tumor and normal tissue and protein level in serum.
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of OPN level (gene and protein) were calculated and the optimal
cut-off value was determined based on the Youden index. In the
Youden index, the maximum vertical distance from the point (x,
y) on the diagonal line of the ROC curve is used [19,20]. The selec-
tion of cutoff points for OPN at each site was undertaken using
ROC-curve analysis. A cut-off value is a value that has the maxi-
mum sensitivity and specificity of the tested marker that discrim-
inate between two groups (patient and healthy subjects) and is a
separator scale. To better evaluate the diagnostic value of OPN,
ROC analysis was performed twice, including the control group
to evaluate the diagnostic accuracy of the parameter to differenti-
ate the patients from the healthy individuals and excluding the
control to assess the ability to discriminates between different
stages of diseases (benign Vs. malignant). P-values < 0.05 were
considered statistically significant.3. Results
3.1. Evaluation of demographic characteristics and biochemical
profiles of patients with various types of bone cancer
The clinic- pathological features of the patients with different
types of malignant and benign bone tumors are summarized in
table 1. As it is obvious, the equal number of most prevalent types
of malignant bone tumors including osteosarcoma, Ewing’s Sar-
coma, and chondrosarcoma also benign bone tumors including
osteochondroma, Giant cell Tumor, and exostosis were enrolled
in the study. There was no significant difference in the age distri-
bution of patients between the groups and in each type of bone
cancer, there were patients aged 40 and under. Only in the chon-
drosarcoma group, all participating patients were over 40 years
old and in the osteochondroma and Giant cell Tumor groups, more
patients were over 40 years old. In this study, both males and
females participated in each group of patients ,and notably, most
of the patients with benign tumors were male. Patients’ tumor
grade was also evaluated as a measure of the severity of their dis-
ease and 18, 12 and 19 out of 27 patients had high-grade tumors inTable 4
The assessed OPN mRNA expression levels in the tumors and paired margins of
patients with primary bone cancers. Mean (95% CI).
Malignancy Type Marginal tissue Cancerous tissue
Malignant Osteosarcoma 0.11 (0.04–0.17) 4.40 (3.71–5.09)a
Chondrosarcoma 0.22 (0.08–0.36) 2.99 (2.56–3.42)b
Ewing sarcoma 0.28 (0.09–0.46) 3.41 (2.92–3.91)ab
Benign Exostosis 0.08 (0.01–0.15) 0.93 (0.80–1.06)c
Giant Cell Tumor 0.07 (0.03–0.11) 1.34 (1.11 – 1.57)c
Osteochondroma 0.06 (0.02–0.11) 1.09 (0.92–1.26)c
Means within a column with different superscript letters (a-c) denote significant
differences (p < 0.05).
Margins Vs. tumors are significantly different (P < 0.0001) within each row.
Table 5
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osteosarcoma, chondrosarcoma and Ewing’s Sarcoma group, sub-
sequently. Also, 17, 19 , and 17 out of 27 patients had a metastatic
tumor in osteosarcoma, chondrosarcoma, and Ewing’s Sarcoma
group, subsequently. In addition, the standard combination of dox-
orubicin, cisplatin, and methotrexate received as a chemotherapy
regimen by patients with osteosarcoma while the chemotherapy
regimen of Ewing’s Sarcoma patients was the combination of vin-
cristine, cyclophosphamide, and doxorubicin and patients with
osteochondroma received no chemotherapy regimen before the
surgery. Accordingly, 18 and 15 patients out of 27 patients in
osteosarcoma and Ewing’s Sarcoma group received chemotherapy
regimens. Local tumor recurrence is a critical complication in
malignant bone tumors [21] and in our survey, 7 patients out of
27 patients in each group of osteosarcoma and Ewing’s Sarcoma
had recurrent tumors. The biochemical profile of the patients is
presented in table 2. The creatine phosphokinase as an indicator
of muscle damage and heart attack showed to be normal in 124
patients (150.36 ± 3.24) while 22 patients were in a high range
(268.25 ± 3.31) of this marker. Alkaline phosphatase as an indicator
of liver disease and bone disorders was also measured in patients
and showed to be normal in 118 patients with bone tumors (196.
72 ± 4.59). The level of Lactate dehydrogenase as an indicator of
injuries and heart failure was in the normal range in 127 patients
(301.94 ± 11.37), while in the high range in 26 patients (1257 ± 22.
38). The level of electrolytes such as calcium, sodium, and potas-
sium was normal in the majority of patients: 125 patients had nor-
mal calcium levels (9.65 ± 0.39), 137 patients had normal sodium
levels (141.35 ± 1.99) and 140 patients had normal potassium level
(4.33 ± 0.35). As indicated, most patients (77–91%) are well within
the normal range for the measured biochemical parameters, except
for inorganic phosphorus, in which only  57% of the patients had
normal values.
3.2. The OPN expression level in different types of primary bone tumors
As shown in Table 4, the OPN mRNA expression levels were sig-
nificantly higher in the cancerous tissues than the paired margins
for all the six subtypes of patients (P < 0.0001). The OPN expression
was also significantly higher in the three malignant tumors
(mean = 3.60, 95% CI = 3.27–3.93) than the benign ones
(mean = 1.10, 95% CI = 0.99–1.21). Moreover, the osteosarcoma
patients showed significantly elevated levels of the mRNA com-
pared to the chondrosarcoma patients. However, no significant dif-
ferences were observed among the benign subtypes. Comparison of
the margins with each other revealed that the mRNA expression is
non-significantly lower in the benign patients than the malignant
counterparts (P > 0.05). As indicated in table 5, both the malignant
and benign patients had significantly higher OPN expression levels
than healthy individuals. Furthermore, the mRNA expression was
found to be significantly higher in the malignant patients
(mean = 0.76, 95% CI = 0.68–0.84) than the benign ones
(mean = 0.31, 95% CI = 0.27–0.35). Although the osteosarcoma
patients tended to have higher mRNA levels, no significant differ-era of the healthy individuals and patients with primary bone cancers. Mean (95% CI).
PBMC Serum
0.05 (0.03–0.06)a 11.71 (10.06–13.35)a
0.88 (0.71–1.02)b 263.68 (218.92–308.41)b
0.72 (0.58–0.86)b 126.43 (106.83–145.92)c
0.69 (0.57–0.81)b 144.41(113.14–175.83)c
0.29 (0.22–0.37)c 55.99 (46.48–65.50)d
0.34 (0.25–0.44)c 74.87 (61.92–87.82)e
0.30 (0.23–0.36)c 73.19 (66.15 – 80.24)e
nces (p < 0.05).
Fig. 1. Comparison of the diagnostic potential of OPN to differentiate between
malignant and benign patients.
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types. Table 5 also represents that parallel to OPN expression levels
in PBMC; its protein concentrations were significantly higher in the
patient cases than the controls. Consistently, its concentration was
also assessed to be significantly higher in the malignant patients
(mean = 178.12, 95% CI = 155.20–201.05) than the benign ones
(mean = 68.02, 95% CI = 62.11–73.93). Interestingly, similar to
OPN mRNA expression in tumors, inter-subtype differences were
noticed among the malignant patients, as OPN concentrations were
remarkably higher in sera of the osteosarcoma patients than the
other patients (p < 0.05). Additionally, the exostosis patients had
significantly lower levels of protein than the others. The cutoff
point, sensitivity, specificity, and AUC are shown in table 6. The
optimal cutoff point was set by the ROC method to > 1.875 for
the OPN mRNA expression in tumor tissues to discriminate
between the malignant and benign patients with 92% and 94% sen-
sitivity and specificity, respectively. The mRNA expression in PBMC
and the corresponding protein levels in serum were also able to
differentiate between the benign and malignant patients, with
acceptable sensitivity and specificity (Fig. 1). Of significant impor-
tance, the protein showed the highest possible accuracy to discrim-
inate the patients from the healthy individuals.
3.3. The OPN differential expression in bone cancer patients with
different demographic features
As shown in Fig. 2, the OPN mRNA expression levels in tumor
tissue were significantly different for all of the assessed clinico-
pathological features in the malignant cases. To be specific, the
mRNA expression in the patients with metastatic, high grade,
and recurrent tumor were notably elevated. However, the expres-
sion in PBMC had no significant difference between the patients
undergoing chemotherapy compared to the untreated cases
(Fig. 3). Moreover, chondrosarcoma patients suffering from meta-
static and high-grade tumors had statistically similar OPN mRNA
levels to the patients with non-metastatic and low-grade tumors
in their PBMC (Fig. 3). Consistently, the OPN protein concentrations
in serum had no significant difference between the patients men-
tioned above (Fig. 4). Interestingly, OPN in PBMC and serum differ-
entiated metastatic, high-grade, and recurrent osteosarcoma and
Ewing sarcoma from the matched counterparts. Like OPN expres-
sion in PBMC, the serum protein concentration had no significant
difference between the osteosarcoma patients undergoing
chemotherapy and the untreated cases (P = 0.0544). However,
the protein level was significantly lower in the treated Ewing sar-
coma patients than the matched untreated patients (P = 0.0292).
3.4. The protein level of OPN in bone tumor tissues
To determine whether the protein level of OPN obeys the same
expression pattern as the OPN gene in tumor and marginal bone
tissues, the OPN protein level was assessed using immunohisto-
chemistry in different types of primary bone tumors. The represen-
tative images of OPN immunohistochemistry staining in primaryTable 6
The ROC curve analysis of OPN for determination of diagnostic sensitivity and specificity
Cutoff point Se
Bone Benign Vs. malignant > 1.875 92
PBMC Control Vs. benign > 0.09 95
Control Vs. malignant > 0.10 10
Benign Vs. malignant > 0.43 86
Serum Control Vs. benign > 26.54 10
Control Vs. malignant > 31.08 10
Benign Vs. malignant > 90.74 81
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bone tumor tissues are illustrated in Fig. 5. Based on our data,
OPN protein expressed more in tumor tissue in each group com-
pared to the matched marginal tissue (P < 0.0001). Also, in malig-
nant bone tumors, the protein level of OPN over-expressed
compared to the benign bone tumors and the difference was statis-
tically significant (P < 0.0001). Osteosarcoma tumors expressed the
highest level of OPN protein compared to Ewing’s Sarcoma
(P = 0.06) and chondrosarcoma (P = 0.0008) tumors (Fig. 5F). Our
data showed that in tumor tissues of patients who received
chemotherapy, the level of OPN protein was higher compared to
the tumor tissues of patients without the history of chemotherapy
in osteosarcoma (P = 0.0237) ,and Ewing’s Sarcoma (P = 0.0072).
OPN protein overexpressed in high-grade osteosarcoma
(P = 0.0079), Ewing’s Sarcoma (P = 0.0107) ,and chondrosarcoma
(P = 0.0344) tumors compared to the low-grade tumors in each
group. Also, the metastatic tumors expressed a higher level of
OPN protein compared to the non-metastatic tumors in osteosar-
coma (P = 0.0049), Ewing’s Sarcoma (P = 0.0376), and chondrosar-
coma (P = 0.0060) group. Our data showed up-regulation of OPN
protein in recurrent osteosarcoma (P = 0.0012) and Ewing’s Sar-
coma (P = 0.0506) bone tumors compared to the non-recurrent
tumors (Fig. 6).
4. Discussion
Although promising progress has been made in diagnostic tech-
niques, particularly medical imaging, the morbidity and mortality
rates are still high in the patients with primary bone tumors due
to lack of specific biomarkers, nonspecific symptoms, and late
patient referring which lead to failure of timely detection and
any therapeutic strategy [4]. There are currently several biomark-in the patients with primary bone cancers.
nsitivity (%) Specificity (%) AUC P-value
94 0.98 <0.0001
97 0.98 <0.0001
0 97 0.99 <0.0001
75 0.88 <0.0001
0 100 1 <0.0001
0 100 1 <0.0001
85 0.90 <0.0001
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can be divided into three main classes, including serologic, genetic,
and histologic. The serological biomarkers are established on
reflecting the osteoblastic and osteoclastic activity of the bone.
These markers come with major limitations, including nonspeci-
ficity (false positive and false negative results), time-consuming
procedure, and unaffordable costs[22]; therefore, cost-effective,
highly sensitive, and specific biomarkers should urgently be inves-
tigated. Tackling the aforementioned shortages, our team has
recently investigated the efficacy of a few novel biomarkers.
Accordingly, we observed that both local and circulating SOX9
were able to differentiate between the malignant and benign
tumors with a strong and positive correlation with tumor severity,
malignancy, size, and chemotherapy suggesting its potential diag-
nostic and prognostic values [17]. Recent studies point to the role
of OPN as an effective mediator in increasing the growth of cancer
cells[23]. Although OPN is a non-collagenous bone matrix protein,
as versatile protein associated with multiple intracellular signaling
pathways, it plays an important role in controlling the growth of
cancer cells[24]. The role of OPN in the pathogenesis of cancer is
important from various aspects including its role in the innate
and adaptive immune system and cytokine production[25], cell
differentiation[26], macrophage recruitment[27], cell adhesion,
and cell migration[28]. Evidence from previous studies suggests
that OPN is involved in multiple stages of cancer progression from
tumor cell proliferation through binding to CD44 and inducing
anti-apoptotic proteins to stimulate angiogenesis by inducing
VEGF and facilitate cell detachment by inducing epithelial-
mesenchymal transition (EMT) phenotype possibly through induc-
ing MMPs[29–31]. The results of the expression pattern of OPN in
different cancers show that OPN can play an effective role in the
pathogenesis of cancer. In accordance, significantly elevated OPN
protein levels were observed in tumors originating from various
human body organs, including breast, ovary, endometrium, esoph-
agus, stomach, pancreas, bile duct, liver, colon, kidney, bladder,
prostate, head and neck, and lung [32]. Consistently, we observed
remarkably higher expression levels of the OPN mRNA and protein
in the patients, highlighting the pivotal role of OPN in the patho-
physiology of primary bone cancers. According to our experiments,
OPN was significantly different between the malignant and theFig. 2. The assessed OPN mRNA expression levels in tumor for the different clinicopa
expression level was evaluated in different types of malignant bone tumors includin
clinicopathological variables (chemotherapy status, tumor grade, tumor metastasis, and r
values.
6
benign patients suggesting a diagnostic potential confirmed by
the ROC method. More importantly, we noticed that the OPN pro-
tein could differentiate between the cases and controls with 100
sensitivity and specificity, inspiring it to be employed as an accu-
rate and non-invasive diagnostic tool. In agreement with our find-
ings, Kim et al. (2002) measured OPN expression in both ovarian
cancerous cell lines and tissue specimens as well as its serum con-
centration and demonstrated that the mRNA expression was sig-
nificantly higher in the cancerous cells/tissues compared to those
of normal/controls. Its protein concentration was also considerably
higher in cancer patients than the healthy individuals, patients
with benign diseases, or other gynecological cancers[33]. In sup-
port of our data, it is postulated that attachment of OPN to the inte-
grin and CD44 receptors mediate activation of PI3K/Akt signaling
pathway that results in tumor cell survival in favor of tumor pro-
gression[34]. Osteosarcoma is the most frequent malignant bone
neoplasm accounting for 30–80% of primary skeletal sarcomas, fol-
lowed by chondrosarcoma and Ewing sarcoma[22]. Interestingly,
we observed that osteosarcoma patients had the highest levels of
OPN in the tissue, PBMC, and serum samples. Both increased and
decreased OPN expression have been reported in osteosarcoma cell
lines; each one has different interpretations. The lower expression
indicates that the majority of osteosarcoma cells fail to undergo
terminal osteogenic differentiation, thereby promoting osteosar-
coma growth, and on the other hand, the elevated expression can
be indicative of the enhanced metastatic ability of osteosarcoma
cells [35,36]. Benign tumors of the bone are not cancerous and
would not metastasize to other regions of the body. However, they
can occur in any part of the skeleton and can still be dangerous as
they may grow and compress healthy bone tissue [37]. In the cur-
rent study, the lowest OPN levels were measured in the samples
taken from patients with exostosis. Generally, among the different
primary bone cancers, osteosarcoma tends to be more aggressive
and invasive than the other five cancers. Conversely, exostosis
tends to be more benign and gentle than the others [38]. Our pre-
liminary research shows that the OPN level is proportional to the
degree of aggressiveness of primary bone tumors, but further
investigations should be conducted on a larger number of samples
to confirm this hypothesis. Based on previous reports, it is postu-
lated that OPN may involve in shaping the tumor microenviron-thological variables in the patients with malignant bone cancers The OPN mRNA
g osteosarcoma (a), Ewing sarcoma(b), and chondrosarcoma (c) for the different
ecurrent) in the patients. The Statistical differences between groups are shown by P
Fig. 3. The assessed OPN mRNA expression levels in PBMC for the different clinicopathological variables in the patients with malignant bone cancers. The OPN mRNA
expression level was evaluated in PBMC of patients in different types of malignant bone tumors including osteosarcoma (a), Ewing sarcoma(b) and chondrosarcoma (c) for the
different clinicopathological variables (chemotherapy status, tumor grade, tumor metastasis and recurrent) in the patients. The Statistical differences between groups are
shown by P values.
Fig. 4. The assessed OPN protein expression levels in serum for the different clinicopathological variables in the patients with malignant bone cancers The OPN protein level
in serum was evaluated in patients with different types of malignant bone tumors including osteosarcoma (a), Ewing sarcoma(b) and chondrosarcoma (c) for the different
clinicopathological variables (chemotherapy status, tumor grade, tumor metastasis and recurrent) in the patients. The Statistical differences between groups are shown by P
values.
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(HIF-1a) pathway and EMT phenotype that results in enhanced
metastasis in breast and ovarian cancer [39,40]. The same mecha-
nism may be assumed for primary bone cancer, and our evidence
has shown that OPN is highly expressed in patients with metasta-
sis and disease severity, but further studies are needed to substan-
tiate this theory.The treatment of osteosarcoma includes
preoperative chemotherapy, followed by surgical removal and
postoperative chemotherapy. Currently, the degree of necrosis in
response to preoperative chemotherapy is used as a reliable prog-
nostic tool to manage postoperative chemotherapy. The patients
are considered to be good responders to the treatment (good prog-
nosis) when the necrosis rate is higher than 90%. Modifying post-
operative chemotherapy can promote the outcomes of poor
responders, and despite the massive efforts, the achievements are7
not satisfactory. Therefore, more efficient prognostic tools are
required to timely predict response to the chemotherapy and guide
the treatment on the right track. To overcome this pitfall, research-
ers are vastly investigating various molecular markers [41]. Our
experiments revealed that the OPN mRNA expression in the tissue
samples from osteosarcoma patients receiving chemotherapy was
around 1.5 folds lower than the untreated counterparts. Moreover,
serum OPN was measured to be around two folds lower in the
osteosarcoma patients without tumor recurrence than the recur-
rent counterparts. In accordance, the association between OPN
and chemoresistance is investigated, recently. It was demonstrated
that OPN can activate the autophagy cell death pathway through
activation of NF- jB pathway in pancreatic cancer cells leading
to chemoresistance to gemcitabine[42]. Moreover, it seems that
the anti- apoptotic effect of OPN may play role in the response of
Fig. 5. The OPN protein level in primary bone tumors. The OPN differential protein expression was assessed in different bone tumor and margin tissues and the OPN
expression level was indicated as the percentage of positive reactivity. Representative images showing the expression of OPN in normal bone tissue; with < 10%
immunoreactivity, 100 (a), tumor tissue; with 32% immunoreactivity, 100.,(b), tumor tissue; with 44% immunoreactivity, 100.(c), tumor tissue with 53.6%
immunoreactivity, 100.(d) and tumor tissue with 57.1% immunoreactivity, 100.(e). The OPN protein expression pattern in malignant, benign and margin tissues is shown
(f). The Statistical differences between groups are shown by P values.
Fig. 6. The OPN protein expression in patients with different malignant bone tumors. The protein level of OPN in tumor tissues of patients with different types of malignant
bone tumors was assessed. The over-expression of OPN was detected in chemotherapy positive, high- grade, metastatic and recurrent tumors in osteosarcoma (a), Ewing
sarcoma(b) and chondrosarcoma (c). The Statistical differences between groups are shown by P values.
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down-regulation of OPN enhanced the sensitivity of breast cancer
cells to the doxorubicin that might be occurred by activating the
p38 MAPK pathway[34,43].
According to our experiments, OPN mRNA expression in PBMC
and its protein level in serum was around 1.7 folds higher in
osteosarcoma patients with metastatic disease than those without
metastatic disease. In support of our findings, Wong et al. (2000)
measured significantly elevated OPN mRNA expression in
osteosarcoma patients compared to healthy individuals. More
importantly, they noticed that 6 of the patients with peripheral
blood OPN mRNA expression exceeding the highest level found
in the healthy subjects developed clinical metastasis within
12 months after the diagnosis. It appears that the elevated mRNA
expression may stem from an increased number of circulating
osteosarcoma cells, and these observations can potentially be
employed as a biomarker for the diagnosis of osteosarcoma
micrometastases and evaluation of prognosis [44].
In the current study, OPN mRNA expression was assessed in
tumor tissue specimens (local) and PBMC (circulating). The lower
mRNA expression in the circulation than the local one is attributa-
ble to the lower populations of undifferentiated cells and cancer8
stem cells in blood than tumors [45]. According to the available
evidence, only a small fraction of the cancer cells may be released
into the bloodstream, making it difficult for detection and evalua-
tion[46]. Considering that mRNA expression might not always end
up in the protein translation due to several genetic and epigenetic
mediators, therefore, in the current study, OPN was assessed at
both mRNA and protein levels to have better insight into the diag-
nostic and prognostic efficacy of OPN. Multiple lines of shreds of
evidence, suggest that OPN can potentially be employed to manage
and monitor the disease in a non-invasive and straightforward
way. In agreement, the results of a meta-analysis by Sun et al.
(2018) demonstrate that OPN can serve as a prognostic biomarker
and a potential therapeutic target for hepatocellular carcinoma as
its level was significantly associated with poor overall survival
and disease-free survival [47]. Another study shows that OPN
levels measured in serum and ascites of women with epithelial
ovarian cancer can reflect the disease outcomes and significantly
contribute to surgical planning [48]. However, our preliminary
study was conducted using a relatively small sample size (153
patients); however, further studies with larger sample sizes are
still required to confirm OPN as a biomarker for primary skeletal
tumors. We also could not perform survival analysis, which is
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This limitation should be addressed in future studies.
5. Conclusion
In conclusion, OPN showed a different expression pattern in
bone tumors with different degrees of deterioration and severity
and a significant increase in its expression in malignant tumors
with high grade and metastasis could indicate its effective role in
bone tumor development. our experiments demonstrated that
OPN may have diagnostic potentials in bone cancer that should
be validated by further studies. Particularly, the OPN protein could
differentiate the patients from the healthy individuals with the
highest possible accuracy and OPN can be employed to manage
and monitor patients with malignant primary bone tumors.
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